| First Author | Li L | Year | 1998 |
| Journal | Biotherapy | Volume | 11 |
| Issue | 4 | Pages | 223-8 |
| PubMed ID | 9950097 | Mgi Jnum | J:52998 |
| Mgi Id | MGI:1331170 | Doi | 10.1023/a:1008054611739 |
| Citation | Li L, et al. (1998) Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide. Biotherapy 11(4):223-8 |
| abstractText | In order to analyse the effector population in an immunization model, we treated BALB/c mice with intraperitoneal (i.p.) active specific immunization (ASI), which consists of interleukin (IL)-1-beta and sonicated tumor supernatant (SS) of a plasmacytoma MOPC-104E followed by i.p. injection of cyclophosphamide (CY). This ASI-CY treatment provoked a protective immunity against i.p. tumor inoculation more strongly than that of ASI alone. The main effector cells in tumor neutralizing assay were CD4+ T cells at this pont. The number of spleen cells of the ASI-CY treated mice were significantly lower than that of ASI alone treated mice but it increased significantly 6 days thereafter while this increase was not observed on the mice treated with ASI alone. The spleen cells of the ASI-CY treated mice responded to SS in vitro in the presence of IL-2, more profoundly in CD4 enriched population which produced high amount of TNF-alpha. In vivo tumor-neutralizing activity at a later stage was dependent on CD8+ T cells in addition to CD4+ T cells. These results suggest that antitumor activity by ASI and CY is transduced by sequential population shift from CD4 alone to both of CD4 and CD8. |
